Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
exenatide (byetta) (1 trial)
insulin human (humulin) (1 trial)
sitagliptin (januvia) (1 trial)
pioglitazone (actos) (1 trial)
saroglitazar (1 trial)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 1 (Phase 4)
Fatty Liver (Phase 3)
Liver Diseases (Phase 3)
Non-alcoholic Fatty Liver Disease (Phase 3)
Trials (2 total)
Trial APIs (5 total)